Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases, Results of the Cardiovascular in Rheumatology (Carma) Project

  • Valero-Jaimes, Jesús A.
  • López-González, Ruth
  • Martín-Martínez, María A.
  • García-Gómez, Carmen
  • Sánchez-Alonso, Fernando
  • Sánchez Costa, Jesús T.
  • González-Juanatey, Carlos|||0000-0002-4483-9778
  • Revuelta-Evrad, Eva
  • Diaz-Torne, Cesar|||0000-0001-6275-7699
  • Fernández-Espartero, Cruz
  • Pérez-García, Carolina|||0000-0002-6695-6406
  • Torrente-Segarra, Vicenç|||0000-0001-6597-3565
  • Sánchez-Nievas, Ginés
  • Pérez-Sandoval, Trinidad
  • Font-Ugalde, Pilar|||0000-0002-0811-9079
  • García Vivar, María Luz|||0000-0001-8822-9843
  • Aurrecoechea, Elena|||0000-0001-6789-7236
  • Maiz-Alonso, Olga
  • Valls-García, Ramón
  • Miranda-Filloy, José A.
  • Llorca, Javier|||0000-0001-8569-861X
  • Castañeda, Santos|||0000-0002-7748-853X
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
Objective: Since obesity has been associated with a higher inflammatory burden and worse response to therapy in patients with chronic inflammatory rheumatic diseases (CIRD), we aimed to confirm the potential association between body mass index (BMI) and disease activity in a large series of patients with CIRDs included in the Spanish CARdiovascular in rheuMAtology (CARMA) registry. Methods: Baseline data analysis of patients included from the CARMA project, a 10-year prospective study of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) attending outpatient rheumatology clinics from 67 Spanish hospitals. Obesity was defined when BMI (kg/m 2) was.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic Analysis with the Immunochip Platform in Behçet Disease. Identification of Residues Associated in the HLA Class I Region and New Susceptibility Loci

  • Ortiz-Fernández, Lourdes|||0000-0002-0247-4280
  • Carmona, F. David|||0000-0002-1427-7639
  • Montes-Cano, Marco-Antonio
  • García-Lozano, José-Raúl
  • Conde-Jaldón, Marta
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Castillo, María Jesús
  • Espinosa, Gerard|||0000-0003-1336-0163
  • Graña, Jenaro|||0000-0001-9041-8117
  • Sánchez Bursón, Juan
  • Juliá, María Rosa
  • Solans, Roser|||0000-0002-0058-1293
  • Blanco, Ricardo|||0000-0003-2344-2285
  • Barnosi-Marín, Ana-Celia
  • Gómez de la Torre, Ricardo
  • Fanlo, Patricia
  • Rodríguez-Carballeira, Mónica|||0000-0002-8802-0238
  • Rodriguez-Rodriguez, Luis|||0000-0002-2869-7861
  • Camps i Miró, Teresa
  • Castañeda, Santos|||0000-0002-7748-853X
  • Alegre-Sancho, Juan José|||0000-0003-1641-0875
  • Martín, Javier|||0000-0002-2202-0622
  • González-Escribano, María Francisca
Behcet's disease (BD) is an immuno-mediated vasculitis in which knowledge of its etiology and genetic basis is limited. To improve the current knowledge, a genetic analysis performed with the Immunochip platform was carried out in a population from Spain. A discovery cohort comprising 278 BD cases and 1,517 unaffected controls were genotyped using the Immunochip platform. The validation step was performed on an independent replication cohort composed of 130 BD cases and 600 additional controls. The strongest association signals were observed in the HLA class I region, being HLA-B*51 the highest peak (overall P = 6.82E-32, OR = 3.82). A step-wise conditional logistic regression with classical alleles identified HLA-B*57 and HLA-A*03 as additional independent markers. The amino acid model that best explained the association, includes the position 97 of the HLA-B molecule and the position 66 of the HLA-A. Among the non-HLA loci, the most significant in the discovery analysis were: IL23R (rs10889664: P = 3.81E-12, OR = 2.00), the JRKL/CNTN5 region (rs2848479: P = 5.00E-08, OR = 1.68) and IL12A (rs1874886: P = 6.67E-08, OR = 1.72), which were confirmed in the validation phase (JRKL/CNTN5 rs2848479: P = 3.29E-10, OR = 1.66; IL12A rs1874886: P = 1.62E-08, OR = 1.61). Our results confirm HLA-B*51 as a primary-association marker in predisposition to BD and suggest additional independent signals within the class I region, specifically in the genes HLA-A and HLA-B. Regarding the non-HLA genes, in addition to IL-23R, previously reported in our population; IL12A, described in other populations, was found to be a BD susceptibility factor also in Spaniards; finally, a new associated locus was found in the JRKL/CNTN5 region.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tocilizumab in refractory Caucasian Takayasu's arteritis, a multicenter study of 54 patients and literature review

  • Prieto-Peña, Diana
  • Bernabeu, Pilar
  • Vela, Paloma|||0000-0001-8566-5172
  • Narváez, Javier|||0000-0002-1614-8064
  • Fernández-López, Jesús C.
  • Freire-González, Mercedes
  • González-Álvarez, Beatriz
  • Solans, Roser|||0000-0002-0058-1293
  • Callejas Rubio, Jose Luis|||0000-0002-1653-0087
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Fernández-Díaz, Carlos
  • Rubio, Esteban
  • García-Morillo, Salvador
  • Minguez, Mauricio
  • Fernández-Carballido, Cristina|||0000-0002-0910-4944
  • Miguel, Eugenio de|||0000-0001-5146-1964
  • Melchor, Sheila
  • Salgado, Eva
  • Bravo, Beatriz
  • Romero-Yuste, Susana
  • Salvatierra, Juan
  • Hidalgo, Cristina
  • Manrique, Sara
  • Romero-Gómez, Carlos
  • Moya, Patricia|||0000-0001-8339-5420
  • Álvarez-Rivas, Noelia
  • Mendizabal, Javier
  • Ortiz Sanjuán, Francisco
  • Pérez de Pedro, Iván
  • Alonso-Valdivielso, José L.|||0000-0002-1862-6883
  • Perez-Sanchez, Laura
  • Roldán, Rosa
  • Fernandez-Llanio, Nagore
  • Gómez de la Torre, Ricardo
  • Suarez, Silvia
  • Montesa Cabrera, María Jesús
  • Delgado Sánchez, Mónica
  • Loricera, Javier|||0000-0003-4754-0277
  • Atienza-Mateo, Belén|||0000-0001-7119-0786
  • Castañeda, Santos|||0000-0002-7748-853X
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
  • Blanco, Ricardo|||0000-0003-2344-2285
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZ) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZ) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZ and 31 (57.4%) on TCZ: MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZ were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases, multicentre study of 80 patients

  • Martín-Varillas, José Luis|||0000-0001-6147-6633
  • Sánchez Bilbao, Lara
  • Calvo-Río, Vanesa
  • Adan Civera, Alfredo|||0000-0002-0849-8814
  • Hernanz, Inés
  • Gallego-Flores, Adela
  • Beltran Catalan, Emma|||0000-0001-8070-6916
  • Castro-Oreiro, Sonia
  • Fanlo, Patricia
  • Garcia Martos, Alvaro
  • Torre, Ignacio
  • Cordero-Coma, Miguel
  • De Dios, Juan Ramon
  • García Aparicio, Ángel
  • Hernández-Garfella, Marisa
  • Sánchez-Andrade, Amalia
  • García-Valle, Andrea
  • Maiz, Olga|||0000-0003-2900-9511
  • Miguélez, Roberto
  • Rodríguez-Montero, Sergio
  • Urruticoechea-Arana, A.
  • Veroz, Raúl
  • Conesa, Arantxa
  • Fernández-Carballido, Cristina|||0000-0002-0910-4944
  • Jovaní, Vega
  • Mondejar, Jose J.
  • Martínez González, Olga
  • Moya, Patricia|||0000-0001-8339-5420
  • Romero-Yuste, Susana
  • Rubio-Muñoz, Paula
  • Peña-Sainz-Pardo, Eva
  • Garijo-Bufort, Marta
  • Demetrio-Pablo, Rosalía
  • Hernández, José Luis|||0000-0002-6585-8847
  • Blanco, Ricardo|||0000-0003-2344-2285
Objectives To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). Methods Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year. Results We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), Conclusions CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.